Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Rating) have earned an average recommendation of “Hold” from the eight research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $4.00.
Several equities analysts have recently issued reports on the company. Canaccord Genuity Group lowered Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Bank of America lowered Neoleukin Therapeutics from a “buy” rating to an “underperform” rating in a research note on Monday, September 12th. Mizuho lowered Neoleukin Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $21.00 to $2.00 in a research note on Tuesday. Canaccord Genuity Group reiterated a “hold” rating on shares of Neoleukin Therapeutics in a research note on Tuesday. Finally, Guggenheim lowered Neoleukin Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday.
Neoleukin Therapeutics Price Performance
Neoleukin Therapeutics stock opened at $0.42 on Tuesday. The stock’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.92. Neoleukin Therapeutics has a one year low of $0.38 and a one year high of $5.95. The firm has a market cap of $17.89 million, a PE ratio of -0.39 and a beta of 1.18.
Institutional Investors Weigh In On Neoleukin Therapeutics
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
- Get a free copy of the StockNews.com research report on Neoleukin Therapeutics (NLTX)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.